Edition:
United States

Tamara Mathias

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Aug 10 2018

Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Aug 09 2018

Perrigo plans to separate prescription pharma business

Perrigo Co Plc said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker's shares down about 8 percent.

Aug 08 2018

Mylan eyes 'all alternatives' as quarterly profit falls short

Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers.

Aug 06 2018

Paratek antibiotic not inferior to current treatments: FDA staff

Paratek Pharmaceuticals Inc's new antibiotic for bacterial pneumonia and skin infections is not inferior to current treatments, U.S. Food and Drug Administration staff reviewers said on Monday.

Aug 02 2018

Regeneron posts quarterly profit beat, strongly backs Eylea's future

Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday, helped by higher sales of its newer medicines and outlined a growth strategy for its flagship drug Eylea, which is facing heightened competition.

Aug 02 2018

Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study

Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.

Aug 01 2018

Humana eyes stronger ties with Walmart despite Walgreens partnership

Humana Inc said it was looking to expand its tie-up with Walmart , easing concerns that the insurer's agreement with drugstore chain Walgreens Boots Alliance would prevent it from broadening its partnership with the retailer.

Jul 31 2018

Pfizer CEO expects Trump to eliminate drug rebates

Pfizer Inc Chief Executive Ian Read said on Tuesday he believes the Trump administration intends to stop the practice of allowing rebates on prescription drug purchases, suggesting that U.S. drug pricing reforms may focus on middlemen rather than drugmakers. | Video

Jul 27 2018

AbbVie cash cow Humira barely beats sales estimates, stock slides

AbbVie Inc's blockbuster arthritis drug Humira barely beat Wall Street sales forecasts, raising concerns about its future viability as a cash cow and sending the drugmaker's shares down 5 percent on Friday.

Jul 26 2018

Celgene profit tops expectations, will limit future price hikes

Celgene Corp on Thursday posted better-than-expected second quarter profit, powered by a 21 percent jump in sales of its blockbuster cancer drug Revlimid, and the U.S. biotech promised to limit future price increases on its medicines. The company joined several rivals in bowing to pressure from the administration of U.S. President Donald Trump to rein in rising costs of prescription drugs to U.S. patients.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary